by Nature Medicine
Developers are encouraged by the robust anti-tumor potency demonstrated by their novel chimeric receptor, the Dual-targeting Synthetic TCR and Antigen Receptor (D-STAR).
by Nature Medicine
Despite ongoing concerns, results from a French database study characterize the risk of secondary cancers after chimeric antigen receptor (CAR) T-cell therapy as very low.
by Alex Kadhim
Recent studies from Rutgers Cancer Institute, Mayo Clinic, Swedish Cancer Institute, and multiple community oncology centers have provided critical insights into the feasibility and safety of...
by Alex Kadhim
A multicenter retrospective study published in Blood Advances, has investigated the impact of prior inotuzumab ozogamicin (InO) treatment on outcomes after brexucabtagene autoleucel (brexu-cel)...
by Blood Advances
Researchers suspect that ablation of the transcription factor Blimp-1 might address the lack of durable efficacy observed with chimeric antigen receptor T-cells (CAR-T) targeting B-cell maturation...
by Rahul Banerjee, MD, FACP
For over 30 years, autologous stem cell transplantation (ASCT) has remained a key component of first-line treatment for multiple myeloma (MM).